BEAM

Beam Therapeutics Inc. - Common Stock (BEAM)

About Beam Therapeutics Inc. - Common Stock (BEAM)

Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.

Details

Daily high

$17.30

Daily low

$16.35

Price at open

$17.16

52 Week High

$35.25

52 Week Low

$13.52

Market cap

1.7B

Dividend yield

0.00%

Volume

247,696

Avg. volume

1.9M

P/E ratio

-3.63

Beam Therapeutics Inc. - Common Stock News